Oramed Pharmaceuticals Inc. (ORMP) |
|
2.15 -0.02 (-0.92%)
|
03-24 16:00 |
|
Open: |
2.16 |
Pre. Close: |
2.17 |
|
High:
|
2.205 |
Low:
|
2.131 |
|
Volume:
|
366,740 |
Market Cap:
|
86(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:28:36 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 2.69 One year: 3.15 |
| Support: |
Support1: 2.02 Support2: 1.85 |
| Resistance: |
Resistance1: 2.3 Resistance2: 2.69 |
| Pivot: |
2.13  |
| Moving Average: |
MA(5): 2.17  MA(20): 2.13
MA(100): 5.44 MA(250): 6.2 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 67.3 %D(3): 71.2 |
| RSI: |
RSI(14): 41.3 |
| 52-week: |
High: 13.72 Low: 1.8 |
| Average Vol(K): |
3-Month: 1,871 (K) 10-Days: 622 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ORMP ] has closed below upper band by 45.1%. Bollinger Bands are 90.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.21 - 2.22 |
2.22 - 2.23 |
|
Low:
|
2.1 - 2.12 |
2.12 - 2.13 |
|
Close:
|
2.13 - 2.15 |
2.15 - 2.17 |
|
Company Description |
|
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York. |
Headline News |
Fri, 24 Mar 2023
Oramed Pharmaceuticals, Inc. (ORMP) Stock: Do Analysts Think You Should Accumulate? - InvestorsObserver
Fri, 24 Mar 2023
Type 2 Diabetes Market to Observe Stunning Growth During the ... - Digital Journal
Wed, 08 Mar 2023
How Does Oramed Pharmaceuticals, Inc. (ORMP) Stock Rank on Wall Street Wednesday? - InvestorsObserver
Thu, 09 Feb 2023
Oramed Pharmaceuticals Issues Shareholder Update - PR Newswire
Mon, 06 Feb 2023
What is the Market's View on Oramed Pharmaceuticals, Inc. (ORMP) Stock's Price and Volume Trends Monday? - InvestorsObserver
Mon, 23 Jan 2023
Analyst Rating: Will Oramed Pharmaceuticals, Inc. (ORMP) Stock Beat the Market? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
39 (M) |
|
% Held by Insiders
|
3.752e+007 (%) |
|
% Held by Institutions
|
5.2 (%) |
|
Shares Short
|
2,690 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.927e+007 |
|
EPS Est Next Qtl
|
-0.28 |
|
EPS Est This Year
|
-0.78 |
|
EPS Est Next Year
|
-1.25 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
817.7 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
2.71e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
1.45699e+006 |
|
Qtrly Earnings Growth
|
-0.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-39 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
2.28 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.75e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
